June 7, 2023 07:35 AM EDT
R&D

Fi­bro­Gen grap­ples with PhI­II set­back in Duchenne mus­cu­lar dy­s­tro­phy

Amber Tong

Fi­bro­Gen’s top an­ti­body can­di­date has failed a Phase III study in Duchenne mus­cu­lar dy­s­tro­phy, mark­ing a dis­ap­point­ing start to a string …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Bris­tol My­ers re­veals more job cuts in New Jer­sey

A service from the Financial Times